SCHEMBL1692013

SCHEMBL1692013

N[C@@H](Cc1ccccc1)C(=O)[CH]Cl

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.63
ALPI P09923 1/20 0.63
PKM P14618 1/20 0.63
PTGS1 P23219 1/20 0.63
XIAP P98170 1/20 0.63
SLC15A1 P46059 2/20 0.54
LTA4H P09960 1/20 0.51
SLC1A3 P43003 2/20 0.50
SLC1A2 P43004 2/20 0.50
SLC1A1 P43005 2/20 0.50
HDAC8 Q9BY41 2/20 0.49
CYP1A2 P05177 1/20 0.47
EPHX1 P07099 2/20 0.47
CTSC P53634 1/20 0.46
LAP3 P28838 3/20 0.46
ANPEP P15144 1/20 0.46
SRR Q9GZT4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28345408 0.83 SLC7A5 (0.66) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL19193059 0.83 SLC7A5 (0.66) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL9295400 0.83 SLC7A5 (0.66) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL11499279 0.81 SLC7A5 (0.63) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL7366481 0.81 SLC7A5 (0.81) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL13367286 0.81 SLC7A5 (0.63) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL14357540 0.79 ALPI (0.59) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL5063628 0.79 SLC7A5 (0.92) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL6744985 0.79 SLC7A5 (0.70) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL7247735 0.79 SLC7A5 (0.70) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1708740-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES Rytek (FR) 2006-10-11 EP claimed
WO-2005077406-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES RYTEK (FR) 2005-08-25 WO claimed
US-12030928-B2 Anti-influenza B virus neuraminidase antibodies and uses thereof ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-07-09 US disclosed
US-20240091337-A1 INFLUENZA B VIRUS MUTANTS AND USES THEREFOR FLUGEN, INC. (US) 2024-03-21 US disclosed
CN-117511844-A Non-invasive method for generating human nasopharyngeal three-and two-dimensional organoids 免疫与感染研究中心有限公司 2024-02-06 CN disclosed
EP-4267610-A1 COMPOSITION OF PIG POLYCLONAL ANTIBODY FOR ITS USE TO TREAT AND/OR PREVENT ANTIBODY-DEPENDENT MACROPHAGE PRO-INFLAMMATORY CYTOKINE RELEASE IN A PASSIVE ANTI-INFECTIOUS IMMUNOTHERAPY Xenothera (FR) 2023-11-01 EP disclosed
EP-4205753-A1 ANTIVIRAL PLANT EXTRACT COMPOSITION AND METHOD FOR PREPARING SUCH COMPOSITION Cariel, Léon (FR) 2023-07-05 EP disclosed
EP-4205754-A1 ANTIVIRAL PLANT EXTRACT COMPOSITION AND METHOD FOR PREPARING SUCH COMPOSITION Cariel, Léon (FR) 2023-07-05 EP disclosed
US-11529409-B2 Influenza B virus mutants and uses therefor FLUGEN, INC. (US) 2022-12-20 US disclosed
WO-2022136505-A1 COMPOSITION OF PIG POLYCLONAL ANTIBODY FOR ITS USE TO TREAT AND/OR PREVENT ANTIBODY-DEPENDENT MACROPHAGE PRO-INFLAMMATORY CYTOKINE RELEASE IN A PASSIVE ANTI-INFECTIOUS IMMUNOTHERAPY XENOTHERA (FR) 2022-06-30 WO disclosed
US-20220153873-A1 ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-05-19 US disclosed
WO-2017183864-A1 COMPOSITION FOR NOROVIRUS CULTURE AND METHOD FOR NOROVIRUS CULTURE 전남대학교산학협력단 2017-10-26 WO disclosed
CN-104780919-A Composition, containing cis-cyclo(l-leu-l-pro) or cis-cyclo(l-phe-l-pro), for use as an antimicrobial and antiviral agent, and preparation method therefor SNU R & D FOUNDATION 2015-07-15 CN disclosed
US-20130165489-A1 Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-06-27 US disclosed
US-20120010103-A1 METHODS OF SCREENING USING AMPHIBIANS BRAENDLI ANDRE W (CH) 2012-01-12 US disclosed
WO-2008136906-A1 PHOTOSENSITIZERS FOR TARGETED PHOTODYNAMIC THERAPY THE GENERAL HOSPITAL CORPORATION (US) 2008-11-13 WO disclosed
EP-1708740-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES Rytek (FR) 2006-10-11 EP disclosed
WO-2005077406-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES RYTEK (FR) 2005-08-25 WO disclosed
CN-1029131-C Process for transforming human insulin precarsor to human insulin LILLY CO ELI (US) 1995-06-28 CN disclosed
CN-87107019-A Method for converting human insulin precursor into human insulin 1988-04-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165489-A1 Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof ZC3HAV1, MAVS, HAVCR2 SLC7A5 2586/4885ALPI 4751/4885PKM 3784/4885
US-20240091337-A1 INFLUENZA B VIRUS MUTANTS AND USES THEREFOR HAVCR2, CMBL, CD81 SLC7A5 3434/4885ALPI 3557/4885PKM 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.